Basu, S. K., Khan, B., Payumo, F., Wan, R., Chiorean, E. G., Gahvari, Z., Hecht, J. R., Hurwitz, M. E., Leidner, R. S., Lenz, H., Pelster, M., Punekar, S. R., Schoenfeld, A. J., Zhao, D., Nagorsen, D. (2025). A phase I study of AFNT-211, autologous CD4
            <sup>+</sup>
            and CD8
            <sup>+</sup>
            T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps2678